An HIV vaccine combining doses of ALVAC from Sanofi-Aventis and AIDSVAX from VaxGen reduced the risk of infection by more than 31%, according to a study involving 16,000 volunteers in Thailand. Although the finding is not seen as a major breakthrough, it could mark the first turning point since Merck & Co.'s HIV vaccine failed to prove effectiveness in human trials in 2007.

Full Story:
Google, Bloomberg

Related Summaries